Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir vs Raltegravir in Treatment-Experienced HIV-1
NCT00708162Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of elvitegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Jul 2008; status: completed.
02
Drugs
elvitegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00708162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00708162.